XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Note 13 - Segment Information
 9 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 13. Segment Information

 

As of December 31, 2020, we had four reportable segments, Sterilization and Disinfection Control, Instruments, Biopharmaceutical Development, and Continuous Monitoring. Results for the Cold Chain Packaging division, which we exited during the year ended March 31, 2020, are now presented within Corporate and Other. The following tables set forth our segment information: 

 

  

Three Months Ended December 31, 2020

 
  

Sterilization and Disinfection Control

  

Instruments

  

Biopharmaceutical Development

  

Continuous Monitoring

  

Corporate and Other

  

Total

 

Revenues (1)

 $13,077  $8,971  $8,711  $3,413  $-  $34,172 

Gross profit (loss)

 $9,308  $5,368  $4,616  $1,501  $(140) $20,653 

Reconciling items (2)

                      (26,380)

(Loss) before income taxes

                     $(5,727)

 

  

Three Months Ended December 31, 2019

 
  

Sterilization and Disinfection Control

  

Instruments

  

Biopharmaceutical Development

  

Continuous Monitoring

  

Corporate and Other

  

Total

 

Revenues (1)

 $11,619  $10,014  $5,637  $4,156  $229  $31,655 

Gross profit (loss)

 $8,101  $6,526  $(1,294) $1,488  $(18) $14,803 

Reconciling items (2)

                      (19,880)

(Loss) before income taxes

                     $(5,077)

 

  

Nine Months Ended December 31, 2020

 
  

Sterilization and Disinfection Control

  

Instruments

  

Biopharmaceutical Development

  

Continuous Monitoring

  

Corporate and Other

  

Total

 

Revenues (1)

 $37,696  $24,209  $23,791  $10,277  $-  $95,973 

Gross profit (loss)

 $28,098  $14,909  $15,294  $4,053  $(76) $62,278 

Reconciling items (2)

                      (64,867)

(Loss) before income taxes

                     $(2,589)

 

  

Nine Months Ended December 31, 2019

 
  

Sterilization and Disinfection Control

  

Instruments

  

Biopharmaceutical Development

  

Continuous Monitoring

  

Corporate and Other

  

Total

 

Revenues (1)

 $35,823  $28,518  $5,637  $11,059  $2,442  $83,479 
Gross profit (loss) $25,334  $18,164  $(1,294) $3,994  $395  $46,593 

Reconciling items (2)

                      (42,471)

Earnings before income taxes

                     $4,122 

 

 

(1)

Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

 

(2)

Reconciling items include selling, general and administrative, research and development, interest expense and amortization of debt discount, and other (income) expenses.

 

The following table sets forth assets by reportable segment: 

 

  

December 31, 2020

  

March 31, 2020

 

Sterilization and Disinfection Control

 $71,706  $73,103 

Instruments

  29,967   31,025 

Biopharmaceutical Development

  205,769   182,758 

Continuous Monitoring

  28,834   29,732 

Corporate and administrative

  285,360   103,588 

Total

 $621,636  $420,206 

 

The increase in total assets was primarily attributable to $145,935 of cash proceeds resulting from the sale and issuance of 600,000 shares of our common stock during the nine months ended December 31, 2020, discussed in Note 8. "Stockholders' Equity", as well the effect of foreign currency translation on assets.